PURIFICATION AND CHARACTERIZATION OF HYPOXIA-INDUCIBLE FACTOR-1

被引:1688
|
作者
WANG, GL
SEMENZA, GL
机构
[1] JOHNS HOPKINS UNIV, SCH MED, CTR GENET MED, DEPT PEDIAT, BALTIMORE, MD 21287 USA
[2] JOHNS HOPKINS UNIV, SCH MED, CTR GENET MED, DEPT MED, BALTIMORE, MD 21287 USA
关键词
D O I
10.1074/jbc.270.3.1230
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hypoxia-inducible factor 1 (HIP-1) is a DNA-binding protein that activates erythropoietin (Epo) gene transcription in Hep3B cells subjected to hypoxia or cobalt chloride treatment. HIF-1 DNA binding activity is also induced by hypoxia or cobalt in non-Epo-producing cells, suggesting a general role for HIF-1 in hypoxia signal transduction and transcriptional regulation. Here we report the biochemical purification of HIF-1 from Epo-producing Hep3B cells and non-Epo-producing HeLa S3 cells. HIF-1 protein was purified 11,250-fold by DEAE ion-exchange and DNA affinity chromatography. Analysis of HIF-1 isolated from a preparative gel shift assay revealed four polypeptides. Peptide mapping of these HIF-1 components demonstrated that 91-, 93-, and 94-kDa polypeptides had similar tryptic maps, whereas the 120-kDa polypeptide had a distinct profile. Glycerol gradient sedimentation analysis suggested that HIF-1 exists predominantly in a heterodimeric form and to a lesser extent as a heterotetramer. Partially purified HIF-1 bound specifically to the wild-type HIF-1 binding site from the EPO enhancer but not to a mutant sequence that lacks hypoxia-inducible enhancer activity. UV cross-linking analysis with purified HIF-1 indicated that both subunits of HIF-1 contact DNA directly. We conclude that in both cobalt chloride treated HeLa cells and hypoxic Hep3B cells HIF-1 is composed of two different subunits: 120-kDa HIF-1 alpha and 91-94-kDa HIF-1 beta.
引用
收藏
页码:1230 / 1237
页数:8
相关论文
共 50 条
  • [31] Hypoxia-Inducible Factor-1α and Autoimmune Lupus, Arthritis
    Yang, Zu-Cheng
    Liu, Yi
    [J]. INFLAMMATION, 2016, 39 (03) : 1268 - 1273
  • [32] Hypoxia-inducible factor-1α regulation of myeloid cells
    C. L. Stothers
    L. Luan
    B. A. Fensterheim
    J. K. Bohannon
    [J]. Journal of Molecular Medicine, 2018, 96 : 1293 - 1306
  • [33] Hypoxia-Inducible Factor-1 in Multiple Myeloma Progression
    Ria, Roberto
    Reale, Antonia
    Berardi, Simona
    Piccoli, Claudia
    Di Pietro, Giulia
    Basile, Antonio
    Capitanio, Nazareno
    Vacca, Angelo
    [J]. BLOOD, 2009, 114 (22) : 720 - 720
  • [34] Honokiol inhibits hypoxia-inducible factor-1 pathway
    Lan, Keng-Li
    Lan, Keng-Hsin
    Sheu, Meei-Ling
    Chen, Ming-Yuan
    Shih, Yi-Sheng
    Hsu, Fu-Chih
    Wang, Hong-Ming
    Liu, Ren-Shyan
    Yen, Sang-Hue
    [J]. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2011, 87 (06) : 579 - 590
  • [35] Hypoxia-inducible factor-1α and the glycolytic phenotype in tumors
    Robey, IF
    Lien, AD
    Welsh, SJ
    Baggett, BK
    Gillies, RJ
    [J]. NEOPLASIA, 2005, 7 (04): : 324 - 330
  • [36] Synthesis of Neolamellarin A, an Inhibitor of Hypoxia-inducible Factor-1
    Arafeh, Khaled M.
    Ullah, Nisar
    [J]. NATURAL PRODUCT COMMUNICATIONS, 2009, 4 (07) : 925 - 926
  • [37] Dexamethasone impairs hypoxia-inducible factor-1 function
    Wagner, A. E.
    Huck, G.
    Stiehl, D. P.
    Jelkmann, W.
    Hellwig-Buergel, T.
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 372 (02) : 336 - 340
  • [38] Cancer Therapy By Targeting Hypoxia-Inducible Factor-1
    Li, Y.
    Ye, D.
    [J]. CURRENT CANCER DRUG TARGETS, 2010, 10 (07) : 782 - 796
  • [39] Characterization of the hypoxia-inducible factor-1 pathway in hearts of Antarctic notothenioid fishes
    O'Brien, K. M.
    Rix, A. S.
    Grove, T. J.
    Sarrimanolis, J.
    Brooking, A.
    Roberts, M.
    Crockett, E. L.
    [J]. COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR BIOLOGY, 2020, 250
  • [40] Chrysin inhibits expression of hypoxia-inducible factor-1α through reducing hypoxia-inducible factor-1α stability and inhibiting its protein synthesis
    Fu, Beibei
    Xue, Jing
    Li, Zhaodong
    Shi, Xianglin
    Jiang, Bing-Hua
    Fang, Jing
    [J]. MOLECULAR CANCER THERAPEUTICS, 2007, 6 (01) : 220 - 226